Michael DiDonato

Jan 10, 2025 | cell.com | Michael DiDonato |David Jones |Damien Picard |Ulrike Sommer |Eric Peters |Shelly L. Meeusen | +10 more

ResultsFor an IL-10 molecule to be effective in the treatment of inflammatory disease, a bioactive protein with an anti-inflammatory profile and an extended half-life is needed. To improve the half-life of IL-10, several standard protein engineering approaches exist, notably PEGylation and Fc fusion.